Genprex Inc (NASDAQ:GNPX) announced Thursday that the United States Adopted Names (USAN) Council approved the generic name quaratusugene ozeplasmid, the company’s non-small cell lung cancer drug formerly known as Oncoprex.
The USAN Council is the agency tasked with selecting simple, unique nonproprietary names for drug candidates. Genprex is also seeking proprietary approval for the brand name GPX-001. Obtaining both approvals is a necessary step in obtaining marketing approval.
“The USAN’s adoption of our non-proprietary name is another step toward advancing our lead drug candidate, GPX-001 for non-small cell lung cancer, toward commercialization,” CEO Rodney Varner said in a statement. “We look forward to the adoption and rollout of a brand name for this drug as we continue to move along the development pathway.”
To preserve the Oncoprex brand, Genprex has renamed its proprietar, non-viral nanoparticle delivery system the Oncoprex Nanoparticle Delivery Platform, which is used to deliver its oncology platform technologies.
“In the meantime, we’ve focused our branding efforts on our proprietary, non-viral nanoparticle delivery system with our recognized Oncoprex name,” Varner added. “We believe this delivery system is a significant differentiator for GPX-001, as well as an important platform delivery system that could be used for additional drug candidates.”
Genprex, based in Austin, Texas, is also developing GPX-002, a gene therapy drug candidate for diabetes.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel